HIV patients gained another treatment option yesterday as the FDA signed off on Emtriva, a once-daily capsule for HIV from Gilead Sciences Inc. (BioWorld Today)

HIV patients gained another treatment option yesterday as the FDA signed off on Emtriva, a once-daily capsule for HIV from Gilead Sciences Inc. (BioWorld Today)

Affymax Inc. closed a $20 million private round of financing that coincided with the drug discovery and development firm's appointment of a new chief executive. (BioWorld Today)